Objective: To investigate the regulation action of Jianji'ning granule(JNG)combined with western medicine on the level of serum acetylcholine receptor antibodies(AchRAb) in myasthenia gravis(MG) patients

so as to offer a theoretical basis of the targeting therapy with AchRAb. Method: Sixty MG patients were randomly divided into trial group (30) and the control group (30)

then the level of serum anti-AchRAb were detected by the enzyme linked immunosorbent assay(ELISA) before and after treatment 6 months

and the clinical efficacy was compared according to the quantitative score of myasthenia gravis(QMG) was measured before and after treatment 3

6 months. Result: The he positive rate of serum AchRAb was about 81.67%(49/60)

the trial group was 83.33% (25/30)

and the control group was 90% (27/30);after 6 months of treatment

the serum AchRAb levels of the trial group(0.721±0.280) mmol·L-1 were significantly lower than that in the control group(0.907±0.387) mmol·L-1

simultaneously the serum AchRAb levels were decreased dramatically compared with the same group before treatment

there wasa significant difference between the two groups (P<0.05).QMG scoring was decreased dramatically in the trial group after treatment compared with the control group (P<0.05)

there was a significant difference

moreover

the total effective rate in the trial group (50%

86.67%)was significantly higher than those in the control groups(23.33%

40%) after 3

6 months of treatment (P<0.05). No obvious adverse reactions appeared in the two groups. Conclusion: The therapeutic effects of JNG combined with western medicine on improvement of clinical symptoms may be due in part to regulation of serum acetylcholine receptor antibody levels of patients

and it is worthy of further studying.